Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma

被引:18
|
作者
Manzano, Mark [1 ,5 ]
Guenther, Thomas [2 ]
Ju, Hyunwoo [3 ]
Nicholas, John [3 ]
Bartom, Elizabeth T. [4 ]
Grundhoff, Adam [2 ]
Gottwein, Eva [1 ]
机构
[1] Northwestern Univ, Dept Microbiol Immunol, Chicago, IL 60611 USA
[2] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany
[3] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[4] Northwestern Univ, Dept Biochem & Mol Genet, Chicago, IL 60611 USA
[5] Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA
来源
MBIO | 2020年 / 11卷 / 04期
基金
美国国家卫生研究院;
关键词
EBNA3C; EBV; HBZ; HTLV-1; IRF4; KSHV; LANA2; master transcription factor; primary effusion lymphoma; super-enhancer; transcriptional reprogramming; vIRF3; DNA-SEQUENCES; TRANSCRIPTION FACTORS; CELL IDENTITY; KSHV; SCREENS; CRISPR; IRF4; MYC; EBV; TRANSFORMATION;
D O I
10.1128/mBio.01457-20
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Kaposi's sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). The cellular transcription factor (TF) interferon (IFN) regulatory factor 4 (IRF4) is an essential oncogene in PEL, but its specific role in PEL and how KSHV deregulates IRF4 remain unknown. Here, we report that the KSHV latency protein viral interferon regulatory factor 3 (vIRF3) cooperates with IRF4 and cellular BATF (basic leucine zipper ATF-like TF) to drive a super-enhancer (SE)-mediated oncogenic transcriptional program in PEL. Chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-Seq) experiments demonstrated that IRF4, vIRF3, and BATF cooccupy the SEs of key survival genes, in a pattern that is distinct from those seen with other IRF4-driven malignancies. All three proteins cooperatively drive SE-mediated IRF4 overexpression. Inactivation of vIRF3 and, to a lesser extent, BATF phenocopies the gene expression changes and loss of cellular viability observed upon inactivation of IRF4. In sum, this work suggests that KSHV vIRF3 and cellular IRF4 and BATF cooperate as oncogenic transcription factors on SEs to promote cellular survival and proliferation in KSHV-associated lymphomas. IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) causes the aggressive disease primary effusion lymphoma (PEL). Here, we show that a viral transcription factor (vIRF3) cooperates with the cellular transcription factor IRF4 to control an oncogenic gene expression program in PEL cells. These proteins promote KSHV-mediated B cell transformation by activating the expression of prosurvival genes through super-enhancers. Our report thus demonstrates that this DNA tumor virus encodes a transcription factor that functions with cellular IRF4 to drive oncogenic transcriptional reprogramming.
引用
收藏
页码:1 / 23
页数:23
相关论文
共 50 条
  • [31] A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus
    Sun, R
    Lin, SF
    Gradoville, L
    Yuan, Y
    Zhu, FX
    Miller, G
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (18) : 10866 - 10871
  • [32] Restricted Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus.
    Horenstein, MG
    Nador, RG
    Chadburn, A
    Knowles, DM
    Cesarman, E
    LABORATORY INVESTIGATION, 1997, 76 (01) : 739 - 739
  • [33] Role of notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression
    Chang, HS
    Dittmer, DP
    Chul, SY
    Hong, YK
    Jung, JU
    JOURNAL OF VIROLOGY, 2005, 79 (22) : 14371 - 14382
  • [34] Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (Spindle) tumor cells
    Staskus, KA
    Zhong, WD
    Gebhard, K
    Herndier, B
    Wang, H
    Renne, R
    Beneke, J
    Pudney, J
    Anderson, DJ
    Ganem, D
    Hasse, AT
    JOURNAL OF VIROLOGY, 1997, 71 (01) : 715 - 719
  • [35] Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus
    Nador, RG
    Cesarman, E
    Chadburn, A
    Dawson, DB
    Ansari, MQ
    Said, J
    Knowles, DM
    BLOOD, 1996, 88 (02) : 645 - 656
  • [36] Kaposi's sarcoma-associated herpesvirus - The high cost of viral survival
    Cesarman, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (12): : 1107 - 1109
  • [37] On the control of late gene expression in Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8)
    Chang, J
    Ganem, D
    JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 2039 - 2047
  • [38] Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen
    Gaidano, G
    Gloghini, A
    Gattei, V
    Rossi, MF
    Cilia, AM
    Godeas, C
    Degan, M
    Perin, T
    Canzonieri, V
    Aldinucci, D
    Saglio, G
    Carbone, A
    Pinto, A
    BLOOD, 1997, 90 (12) : 4894 - 4900
  • [40] Conservation of virally encoded MicroRNAs in kaposi sarcoma-associated herpesvirus in primary effusion lymphoma cell lines and in patients with kaposi sarcoma or multicentric Castleman disease
    Marshall, Vickie
    Parks, Thomas
    Bagni, Rachel
    Wang, Cheng Dian
    Samols, Mark A.
    Hu, Jianhong
    Wyvil, Kathleen M.
    Aleman, Karen
    Little, Richard F.
    Yarchoan, Robert
    Renne, Rolf
    Whitby, Denise
    JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (05): : 645 - 659